A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain. by Tyree, Griffin A et al.
UC San Diego
UC San Diego Previously Published Works
Title
A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic 
Neuropathic Pain.
Permalink
https://escholarship.org/uc/item/3tq8w2f0
Journal
Cannabis and cannabinoid research, 4(1)
ISSN
2378-8763
Authors
Tyree, Griffin A
Sarkar, Reith
Bellows, Brandon K
et al.
Publication Date
2019
DOI
10.1089/can.2018.0027
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
A Cost-Effectiveness Model for Adjunctive Smoked
Cannabis in the Treatment of Chronic Neuropathic Pain
Grifﬁn A. Tyree,1 Reith Sarkar,1 Brandon K. Bellows,2 Ronald J. Ellis,3–5 Joseph Hampton Atkinson,3,4 Thomas D. Marcotte,3,4
Mark S. Wallace,4,6 Igor Grant,3,4 Yuyan Shi,7 James D. Murphy,8 and David J. Grelotti3,4,*
Abstract
Background: A recent meta-analysis afﬁrmed the beneﬁt of medicinal cannabis for chronic neuropathic pain, a
disabling and difﬁcult-to-treat condition. As medicinal cannabis use is becoming increasingly prevalent among
Americans, an exploration of its economic feasibility is warranted. We present this cost-effectiveness analysis of
adjunctive cannabis pharmacotherapy for chronic peripheral neuropathy.
Materials and Methods: A published Markovmodel comparing conventional therapies for painful diabetic neuro-
pathy was modiﬁed to include arms for augmenting ﬁrst-line, second-line (if ﬁrst-line failed), or third-line (if ﬁrst-
and second-line failed) therapies with smoked cannabis. Microsimulation of 1,000,000 patients compared the cost
(2017 U.S. dollars) and effectiveness (quality-adjusted life years [QALYs]) of usual care with and without adjunctive
cannabis using a composite of third-party and out-of-pocket costs. Model efﬁcacy inputs for cannabis were adapted
from clinical trial data. Adverse event rates were derived from a prospective study of cannabis for chronic non-
cancer pain and applied to probability inputs for conventional therapies. Cannabis cost was derived from retail mar-
ket pricing. Parameter uncertainty was addressed with one-way and probabilistic sensitivity analysis.
Results: Adding cannabis to ﬁrst-line therapy was incrementally less effective and costlier than adding cannabis to
second-line and third-line therapies. Third-line adjunctive cannabis was subject to extended dominance, that is, the
second-line strategy was more effective with a more favorable incremental cost-effectiveness ratio of $48,594 per
QALY gained, and therefore, third-line adjunctive cannabis was not as cost-effective. At a modest willingness-to-pay
threshold of $100,000/QALY gained, second-line adjunctive cannabis was the strategy most likely to be cost-effective.
Conclusion: As recently proposed willingness-to-pay thresholds for the United States health marketplace range
from $110,000 to $300,000 per QALY, cannabis appears cost-effective when augmenting second-line treatment
for painful neuropathy. Further research is warranted to explore the long-term beneﬁt of smoked cannabis and
standardization of its dosing for chronic neuropathic pain.
Keywords: cost-effectiveness; medical marijuana; painful neuropathy; diabetic neuropathy; HIV neuropathy
Introduction
A growing body of scientiﬁc literature demonstrates re-
producible efﬁcacy of cannabis in the treatment of sev-
eral medical conditions, including chronic neuropathic
pain. Clinical trials of oral,1–5 smoked,6–9 and vapor-
ized10,11 cannabis and cannabinoids have all demon-
strated analgesic beneﬁt of medicinal cannabis in the
treatment of this costly12 and disabling13,14 condition.
A recent meta-analysis of individual patient data
from ﬁve randomized controlled trials of inhaled
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cannabis demonstrated pain relief comparable to gaba-
pentin.15 Treatment guidelines for neuropathic pain
recommend consideration of cannabinoids as third-
line agents.16
An increasing number of patients are using cannabis
for medical reasons,17–23 but how do we know if the
health beneﬁts gained with medicinal cannabis are worth
the added cost? Cost-effectiveness analysis (CEA) com-
pares the costs and health beneﬁts of two or more inter-
ventions to determine their value. A treatment is
considered cost-effective when the ratio of incremental
costs to incremental health beneﬁts, known as the in-
cremental cost-effectiveness ratio (ICER),24 is less than
a health care payer’s willingness to pay for the health
beneﬁt. Quality-adjusted life years (QALYs), which in-
corporate both quality of life and longevity, are the rec-
ommended measure of health beneﬁt.24,25
Conversely, treatment is considered dominated—
and categorically not cost-effective—when it is less ef-
fective but more costly than an alternative, and extend-
edly dominated when there is another treatment
alternative to usual care with a lower ICER value. In
the United States, $50,000 per QALY is a commonly
accepted willingness-to-pay threshold, but expert opin-
ion estimates that it likely ranges from $110,000 to
$300,000 per QALY.26–28
To our knowledge, the only cost-effectiveness studies
of cannabis or cannabinoids evaluated nabiximols and
dronabinol for multiple sclerosis (MS),29 and no stud-
ies have assessed the cost-effectiveness of smoked me-
dicinal cannabis for any condition. As federal
regulations prohibit health plans from covering medic-
inal cannabis and patient expenses are out-of-pocket,
knowing the cost-effectiveness of medicinal cannabis
may impact how providers advise its use in patients
suffering from chronic neuropathic pain.
As the majority of patients in placebo-controlled tri-
als of medicinal cannabis were administered cannabis
in addition to an existing pain regimen,6–8,11 there is
sufﬁcient data to support an exploratory study of the
cost-effectiveness of smoked cannabis as adjunctive
therapy in the treatment of chronic neuropathic pain.
The purpose of this exploratory computer simulation
study was to assess the cost-effectiveness of augment-
ing ﬁrst-line, second-line, or third-line standard thera-
pies for neuropathic pain with smoked cannabis in
treatment-naive patients over 1 year from a U.S. health
care sector perspective. We also sought to assess the ro-
bustness of our simulation to changes in parameter in-
puts and assumptions.30
Materials and Methods
Overview
CEAs often use branching decision models constructed
in specialized software to compare interventions in
simulated patients. In CEA models, simulated patients
experience clinical outcomes related to health state util-
ity and decrements (e.g., clinical improvement, intoler-
able side effects, or death) and incur costs (e.g.,
prescription medication ﬁlls, physician ofﬁce visits, or
hospitalizations) based on input probabilities, which
are commonly derived from published literature.30
For this analysis, we constructed a CEA model by
adding adjunctive cannabis to the treatment arms of
a published microsimulation (i.e., individual-patient
simulation) model of painful diabetic peripheral neuro-
pathy (pDPN).31 While the efﬁcacy of smoked canna-
bis from clinical trials represents a heterogeneous
group of conditions causing neuropathic pain, we did
not identify a published microsimulation model for
chronic neuropathic pain due to mixed etiologies.
Although multiple published CEAs of chronic neuro-
pathic pain due to a single etiology were identiﬁed,31–34
the model by Bellows et al. best approximated clini-
cal practice by allowing patients to switch between stan-
dard therapy agents when they experienced poor pain
relief or adverse events.31
We therefore adapted this model to estimate the costs
(2017 U.S. dollars), QALYs, and cost-effectiveness of
augmenting standard therapy agents for neuropathic
pain with smoked cannabis by adding parameters to
simulate adjunctive cannabis use.
Model structure
We simulated the cost and QALY outcomes of 1,000,000
treatment-naive patients newly diagnosed with neuro-
pathic pain. Following Bellows et al., baseline age and
pain score were assigned from normal distributions de-
rived from pooled, weighted means and standard devia-
tions from clinical trials of four standard therapy agents
for neuropathic pain (i.e., desipramine, duloxetine,
gabapentin, and pregabalin).31 As the previous analysis
found that initiating duloxetine in treatment-naive pa-
tients with pDPN was the most cost-effective ﬁrst-line
therapy,31 we assumed that each patient would receive
standard therapy beginning with duloxetine.
In the event of drug failure, patients then switched
randomly to one of three remaining standard therapy
agents. In our model, adjunctive cannabis was initiated
according to four treatment strategies: (1) never (the
‘‘usual care’’ arm), (2) at the start of treatment (ﬁrst-
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line adjunctive cannabis), (3) after failing one standard
therapy agent (second-line adjunctive cannabis), or (4)
after failing two standard therapy agents (third-line ad-
junctive cannabis).
All patients began the simulation in the moderate-
to-severe pain state (i.e., score ‡4 on an 11-point Likert
scale). Patients were assessed stepwise for mortality,
adherence, adverse events, and pain relief following
procedures developed by Bellows et al.31 modiﬁed to
a 6-week cycle to account for additional pain relief
and/or adverse events related to adjunctive cannabis
use (Fig. 1). Six-week cycle length was selected as this
represents a patient with moderate-to-severe pain
whose treatment is actively being optimized.
At the end of each 6-week cycle, patients with a pain
score <4 were assumed to have good pain relief and im-
proved quality of life. If so, patients would remain on
that treatment. Patients with a pain score ‡4 had
poor pain relief and decreased quality of life. If patients
had two or more 6-week cycles of inadequate pain con-
trol or experienced intolerable or serious adverse events
(SAEs) in any one cycle, it was assumed that they
would switch drugs. Patients who were nonadherent
to adjunctive cannabis experienced poor pain relief
through two cycles of adjunctive cannabis treatment, or
experienced intolerable or SAEs while taking adjunctive
cannabis, were considered to have failed cannabis and
could not restart the drug.
Model inputs
Parameters selected for the model, model inputs, and
their distribution types are presented in Table 1.
Model inputs for the efﬁcacy and adverse event rates
of standard therapy agents were extracted from Bellows
et al.31 Costs were assessed from a U.S. health care sector
perspective, which incorporates both third-party payer
direct medical costs (i.e., what insurers pay) and patient
out-of-pocket costs, to account for both health plan-
covered prescription medications and medicinal canna-
bis, which patients must pay for themselves.24 The cost
of standard therapy agents, health state utility, and util-
ity decrements due to adverse events were adapted from
Bellows et al. (SupplementaryTable S1).31
To derive parameters for efﬁcacy of smoked canna-
bis, we examined clinical trials of whole-plant cannabis
in adults with chronic peripheral neuropathic pain if
the study drug was administered in cigarette form, 24-
h average pain scores were reported, pain reduction was
FIG. 1. Abbreviated model overview. Pictured is a node structure wherein adjunctive cannabis is integrated
into a treatment model using standard therapy agents described by Bellows et al.31 Beginning in a moderate-
to-severe pain health state, simulated patients are assessed stepwise for mortality, adherence, tolerable or
intolerable adverse events, SAE, and quality of pain relief. Patients who die are removed from the simulation
and do not transition further. Nonadherence disqualiﬁes a patient from experiencing either pain relief or
adverse events from a given agent. Serious or intolerable adverse events trigger discontinuation of current
therapy (with or without adjunctive cannabis) and drug-switching. Patients who attain good pain relief (pain
score <4) transition to the mild pain state at the end of the cycle. In the absence of good pain relief, patients
remain in moderate-to-severe pain at the end of the cycle. SAE, serious adverse events.
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reported on a numeric or Likert scale, duration was
‡5 days, and results were published in English. We
considered all etiologies for neuropathic pain. Two tri-
als in HIV-associated sensory neuropathy were identi-
ﬁed which met our criteria.6,7 However, we required
access to study data to extract mean pain score reduc-
tions. Only Ellis et al. provided data for their study.
Data from the other trial were not easily accessible
(Donald Abrams, personal communication).
We converted the pain score reduction measures
from a 100-point visual analog scale to an 11-point Lik-
ert scale to align with the parameters for standard
therapy agents. We modeled the efﬁcacy of adjunctive
cannabis using the mean difference in pain score
reductions between active cannabis and placebo ciga-
rettes.
To model the change in probability of adverse events
when cannabis is used to augment standard therapy, we
applied a modiﬁer to adverse event rates for standard
therapy agents. This modiﬁer was derived from ad-
justed odds ratios (ORs) for non-SAE and SAE calcu-
lated in the Cannabis for the Management of Pain:
Table 1. Parameter Distribution Inputs
Parameter Model inputs
Distribution
type
Baseline values,31 mean (SD)
Age 59.72 (9.79) Normal
Pain score 6.20 (1.52) Normal
Pain score reduction,31 mean (SD)
Duloxetine 2.57 (2.31) Normal
Desipramine 1.99 (2.16) Normal
Gabapentin 2.42 (2.34) Normal
Pregabalin31 2.59 (1.87) Normal
Cannabis35 1.11 (2.38) Normal
Probability of nonserious AEs,31 proportion (SE)
Duloxetine 66.0% (1.2%) Beta
Desipramine 74.4% (4.9%) Beta
Gabapentin 66.4% (2.5%) Beta
Pregabalin 69.1% (1.5%) Beta
Cannabis35,a 58.6% (3.4%) Beta
Probability of intolerable AEs,31 proportion (SE)
Duloxetine 15.7% (1.2%) Beta
Desipramine 13.8% (4.5%) Beta
Gabapentin 14.7% (2.3%) Beta
Pregabalin 12.5% (1.3%) Beta
Cannabis35,a 4.6% (1.4%) Beta
Probability of serious AEs,31 proportion (SE)
Duloxetine 2.4% (0.4%) Beta
Desipramine 1.3% (1.3%) Beta
Gabapentin 4.0% (1.1%) Beta
Pregabalin 2.6% (0.5%) Beta
Cannabis35,a 0.5% (0.5%) Beta
Cannabis AE risk modiﬁer,35 odds ratio (95% CI)
Nonserious AEs 1.74 (1.42–2.14b) Logistic
Nonserious AEs—no
active use
2.07 (1.59–2.70b) Logistic
Serious AEs 1.08 (0.57–2.04b) Logistic
Serious AEs—no
active use
1.77 (0.72–4.32b) Logistic
Risk of death from SAE59 (by age, years), proportion (SE)
18–44 1.2% (0.1%) Beta
45–64 1.6% (0.2%) Beta
65–84 1.9% (0.2%) Beta
‡ 85 2.6% (0.6%) Beta
Adherence,60 mean (SD)
Duloxetine 0.86 (0.18) Beta
Desipramine 0.76 (0.24) Beta
Gabapentin 0.74 (0.24) Beta
Pregabalin 0.69 (0.25) Beta
Cannabis36 0.84 (95% CI: 0.78–0.90b) Beta
Adherence thresholdc
(assumed)
0.8 (range: 0.5–1.0) Triangular
Discontinuation rate,31 proportion (SE)
Duloxetine 1.7% (0.4%) Beta
Desipramine 2.6% (1.8%) Beta
Gabapentin 2.3% (0.8%) Beta
Pregabalin 3.9% (0.7%) Beta
Cannabis35 10.7% (2.1%) Beta
Health state utilities,13 mean (SD)
Mild pain 0.7 (0.2) Beta
Moderate-to-severe pain 0.39 (0.33) Beta
Utility decrements, mean
Tolerable AE61,62 0.05d Beta
Intolerable AE63–65 0.11d Beta
Serious AE64,66,67 0.12d Beta
Ofﬁce visit costs,68 mean (SD)
Regular visit $111 ($7) Gamma
SAE visit $150 ($10) Gamma
$51 ($4) Gamma
(continued)
Table 1. (Continued)
Parameter Model inputs
Distribution
type
Regular visit, out-
of-pocket69
SAE visit, out-of-pocket69 $57 ($8) Gamma
SAE hospitalization costs59 (by age, years), mean (SE)
18–44 $7,387 ($130) Gamma
45–64 $9,447 ($165) Gamma
65–84 $9,664 ($292) Gamma
‡ 85 $8,658 ($340) Gamma
Hospitalization out-of-
pocket costs70
$70 ($37) Gamma
Standard therapy wholesale costs31,71 (1 month supply), mean (SD)
Duloxetine $254 ($20) Gamma
Desipramine $236 ($58) Gamma
Gabapentin $305 ($99) Gamma
Pregabalin $485 ($33) Gamma
Standard therapy out-of-pocket costs,71,72 mean (SE)
Duloxetine $13.00 ($2.34) Gamma
Desipramine $22.25 ($7.04) Gamma
Gabapentin $8.79 ($3.54) Gamma
Pregabalin $19.63 ($9.98) Gamma
Cannabis cost, mean (SD)
Price per gram37 $11.06 ($3.78) Gamma
Cannabis quantiﬁcation6
Daily grams THC 0.067 (0.034) Gamma
Cannabis wastage 38.9% (13.2%) Beta
aFor cannabis ‘‘monotherapy,’’ when patient is nonadherent to con-
ventional agent but adherent to cannabis.
bDistribution SD estimated as 1/4 of 95% CI.
cRange and distribution for adherence threshold used in probabilistic
sensitivity analysis only.
dDistribution SD estimated as 1/2 of mean value.
AE, adverse event; CI, conﬁdence interval; SAE, serious adverse event;
SD, standard deviation; SE, standard error; THC, tetrahydrocannabinol.
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Assessment of Safety Study (COMPASS),35 which
compared safety outcomes between chronic pain pa-
tients who did and did not self-treat with cannabis
over a 1-year timeframe. When patients were nonad-
herent to standard therapy but adherent to cannabis,
adverse event rates were derived from the proportion
of participants in COMPASS who were exposed to can-
nabis and experienced adverse events that investigators
considered related to the drug.
Dosing of cannabis was based on the administration
schedule used by Ellis et al., that is, four times daily.6
Literature on adherence to medicinal cannabis is
sparse, and no published study reports cannabis adher-
ence as a scalar variable. Therefore, we estimated ad-
herence to smoking cannabis four times daily as
adherence to a four times daily-dosed medication in
chronic disease, reported in a recent meta-analysis.36
We derived the cost per gram of cannabis ﬂower from
a study of transactions in theWashington state legal mar-
ketplace from 2014 to 2016.37 We modeled a cannabis
whole-plant product containing 12.5% tetrahydrocan-
nabinol (THC), which emulates the study cannabis
used in COMPASS.35 The daily dose of THCwas derived
from the average daily dose delivered to participants by
Ellis et al. in their clinical trial,6 a dose individually ti-
trated to balance pain relief and tolerability.
Analysis
Effectiveness of each treatment strategy was expressed
in QALYs. In the model, QALYs for each 6-week
cycle were calculated by multiplying the utility of a pa-
tient’s health state, determined by pain relief and ad-
verse events, by the time spent in that health state.30
Utility, a measure of quality of life assigns a value be-
tween 0 (death) and 1 (perfect health) to represent se-
verity of disability in a health state. Costs were also
assessed on a 6-week cycle. Costs included both
third-party and out-of-pocket costs due to the standard
therapy agents, costs of an ofﬁce visit to a physician or
hospitalization, and, where applicable, costs of adjunc-
tive cannabis. The cost-effectiveness of treatment arms
was expressed using ICERs. We adjusted costs and
QALYs at a rate 3% annually to account for inﬂation
and adjusted future utility gains to their value at pres-
ent.24 All analyses were performed using TreeAge Pro
2018 (TreeAge Software, Inc., Williamstown, MA).
Base-case analysis. The goals of our analysis were two-
fold. First, we evaluated whether any adjunctive canna-
bis strategy was cost-effective compared to usual care by
determining if the calculated ICER was at or below
a willingness-to-pay threshold of $100,000 per QALY.
Second, we compared the relative cost-effectiveness
of ﬁrst-line, second-line, and third-line adjunctive can-
nabis to determine the strategy associated with the
greatest value.
Sensitivity analysis. To assess the robustness of our
ﬁndings to variations in model parameters—as some
parameters may ﬂuctuate in clinical practice—we per-
formed both one-way and probabilistic sensitivity ana-
lyses. This is especially relevant to medicinal cannabis
for which prices ﬂuctuate widely by region and retailer
and for which there remains uncertainty regarding
long-term efﬁcacy and rates of adverse events.37–40
In one-way sensitivity analysis, the model is run for
multiple iterations and the mean of a single parameter
is varied over a speciﬁed range. For cannabis adverse
event rate modiﬁers and adherence to adjunctive can-
nabis, we deﬁned this range as the 95% conﬁdence in-
terval of reported ORs. Mild pain health state utility,
cannabis price per gram, daily THC dose, and ad-
herence to standard therapy agents were all varied
over –one standard deviation from the mean. Adher-
ence threshold was varied from 0.5 to 1.0 (i.e., 50% ad-
herence to 100% adherence). Non-SAE probabilities
were varied over –25% from the mean. All other pa-
rameters were varied over –50% from the mean value.
We also performed probabilistic sensitivity anal-
ysis to account for uncertainty across all parame-
ters at once. The model was run 10,000 times with
new parameter values selected at each iteration from
the model distributions used in base-case analysis
(Table 1). While adherence threshold was static in
base-case analysis, in probabilistic sensitivity analysis,
it was sampled from a triangular distribution from
0.5 to 1.0. The resulting QALYs and costs were used
to determine the relative cost-effectiveness of each
treatment plan. The proportion of model iterations,
in which a given treatment plan was most cost-effective
compared to all other treatment arms, was plotted
against a range of willingness-to-play thresholds, the
cost-per-QALY value up to which interventions are
considered cost-effective in a given context.
Alternate time horizons. In base-case, our model was
analyzed with a 1-year time horizon. This was a func-
tion of limited data in the literature: the longest time-
frame, in which adverse events were followed for
users of a medicinal cannabis regimen, was 1 year.35
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As use of an analgesic regimen beyond 1 year is more
reﬂective of clinical practice for a chronic condition
such as painful neuropathy, we examined the model
with extended time horizons of 5 and 10 years. How-
ever, these estimates were highly exploratory as data
on the efﬁcacy and adverse effects of medicinal canna-
bis use in that timeframe are unavailable.
Alternate adverse event modifiers. Adverse event rate
modiﬁers for cannabis-containing regimens were de-
rived from adjusted ORs calculated in an observational
cohort study, in which 65.6% of participants in the
cannabis-exposed group were current users at base-
line.35 Tolerance to adverse effects has been observed
after repeated dosing.41 ORs for all adverse events
and SAEs were higher when active cannabis users
were excluded from analysis. We conducted a subanal-
ysis using these ORs to simulate starting medicinal can-
nabis in a population who are not active users.
Cannabis wastage. The base-case model assumes that
patients use cannabis with a high degree of efﬁciency,
consuming only the amount corresponding to their
prescribed dose of THC. To simulate loss of cannabis
to waste (and the need to purchase a somewhat larger
quantity of the drug than in base-case), we calculated
a cannabis wastage term using supplemental data pro-
vided by Ellis et al.6—deﬁned as the proportion of un-
used cannabis cigarette at the end of a smoking session
multiplied by THC concentration—and applied it to
our model.
Results
Base-case analysis
The results of the base-case analysis are presented in
Table 2. In the base-case analysis, usual care had the
lowest mean cost ($6,397) per patient, followed by
third-line ($6,641), second-line ($7,007), and ﬁrst-line
adjunctive cannabis strategies ($7,234). Second-line ad-
junctive cannabis provided the greatest average QALYs
per patient (0.489), followed by ﬁrst-line (0.488) and
third-line (0.480) adjunctive cannabis, then usual care
(0.476).
As it costs more while being less effective than
second-line adjunctive cannabis, ﬁrst-line adjunctive
cannabis was dominated and not considered further.
While both second- and third-line adjunctive cannabis
strategies were more effective than usual care, second-
line adjunctive cannabis yielded more QALYs and had
a more favorable ICER versus usual care; thus, third-
line adjunctive cannabis was extendedly dominated
and not considered further. Second-line adjunctive
cannabis was cost-effective compared to usual care,
with an ICER of $48,594 per QALY gained.
Sensitivity analyses
As second-line adjunctive cannabis dominated or
extendedly dominated both ﬁrst-line and third-line
strategies in base-case analysis, we structured one-way
sensitivity analyses comparing second-line cannabis
with usual care (Fig. 2). Our model was most sensitive
to changes in adherence threshold, mild pain state
utility, and moderate-to-severe pain state utility. The
model was also sensitive—to a lesser extent—to
changes in cannabis adherence and daily THC dose.
For example, when cannabis adherence was reduced
from 84% in base-case to 78%, the ICER for second-
line adjunctive cannabis tripled to $145,292 per
QALY. When daily THC dose required was raised
from 0.067 to 0.101 g per day, the ICER for second-
line cannabis increased to $68,220 per QALY.
In probabilistic sensitivity analysis, usual care was
most likely to be cost-effective up to a willingness-to-
pay threshold of $60,000 per QALY (Fig. 3). Above
$60,000 per QALY second-line adjunctive cannabis
was the most cost-effective strategy, with a 62% proba-
bility of being the most cost-effective strategy at a
willingness-to-pay threshold of $100,000 per QALY.
Table 2. Average Cost and Efﬁcacy of Base-Case Analysis
Treatment strategy
Average Incremental
ICER ($/QALY gained)Cost ($U.S.) Efficacy (QALY) Cost Efficacy
Usual care $6,397 0.476 REF REF REF
First-line adjunctive cannabis $7,234 0.488 — — Dominated
Second-line adjunctive cannabis $7,007 0.489 $610 0.013 $48,594
Third-line adjunctive cannabis $6,641 0.480 — — Ext. dominated
All costs are in 2017 U.S. dollars. ICERs are calculated referent to the next least costly nondominated treatment option.
ICER, incremental cost-effectiveness ratio; REF, reference value; Ext. dominated, extendedly dominated; QALY, quality-adjusted life-years.
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FIG. 2. One-way sensitivity analysis tornado diagram. ICER represents the incremental cost per QALY gained
from second-line adjunctive cannabis when compared to usual care. The dotted vertical line represents the
base-case ICER of $48,594/QALY, while the horizontal bars indicate the magnitude of change in ICER caused by
varying the parameter over its speciﬁed range. A negative ICER value, at which second-line adjunctive cannabis
was dominated by usual care, is represented by an arrow tip on the end of the horizontal bar. All variables were
examined in analysis; the ﬁve parameters shown caused the greatest change in ICER. Varying adherence
threshold caused usual care to dominate second-line adjunctive cannabis. Varying moderate-to-severe pain
state utility, mild pain state utility, and adherence to adjunctive cannabis over their respective ranges for
sensitivity analysis caused the ICER to cross the $100,000/QALY threshold and second-line adjunctive cannabis
to lose cost-effectiveness. However, second-line adjunctive cannabis remained cost-effective across the range
of values for daily THC dose inputs. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year;
THC, tetrahydrocannabinol.
FIG. 3. Cost-effectiveness acceptability curve from probabilistic sensitivity analysis. Percentage of iterations,
in which a given treatment strategy is most cost-effective, was plotted against escalating willingness-to-pay
thresholds. In our model, cannabis-containing strategies were most cost-effective at willingness-to-pay
thresholds of approximately $60,000 per QALY gained and above.
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Alternate time horizons
Adjunctive cannabis remained cost-effective in analy-
ses using time horizons of 5 and 10 years (Table 3).
First-line adjunctive cannabis was dominated in all
alternate timeframes, while third-line adjunctive can-
nabis was no longer extendedly dominated by second-
line adjunctive cannabis, with more favorable ICERs
over both 5- and 10-year time horizons.
Alternate adverse event rate modiﬁers
When the adverse event rate modiﬁers for cannabis were
adjusted to reﬂect the exclusion of active cannabis users
from the patient cohort, second-line adjunctive cannabis
continued to dominate other cannabis-containing strat-
egies (Table 3). The strategy produced a slightly lower
increase in efﬁcacy from base-case (0.010 from 0.013),
with a slight increase in incremental cost ($788 from
$610), which resulted in an ICER of $73,193 per QALY.
Cannabis wastage
Results of cannabis wastage subanalysis are presented in
Table 3. As in base-case analysis, second-line adjunctive
cannabis dominated ﬁrst-line and third-line adjunctive
cannabis. Applying cannabis wastage to the base-case
model resulted in a signiﬁcantly higher ICER ($83,865
per QALY).
Discussion
In this exploratory CEA of smoked cannabis for neuro-
pathic pain, we found augmentation of standard therapy
agents for neuropathic pain with smoked cannabis to be
cost-effective over the short- and long-term with ICERs
below our designated threshold of $100,000 per QALY.
This held true when parameters were varied over their
distribution ranges in probabilistic sensitivity analysis,
and when more stringent inputs for adverse event
rates and cannabis wastage were modeled.
First-line adjunctive cannabis was dominated by
other adjunctive cannabis strategies, as exposing the
entire cohort of patients to the increased risk of non-
SAEs associated with cannabis use appeared to out-
weigh any signiﬁcant gains in pain control. In contrast,
when patients started cannabis after failing one or
more drugs—through either repeated rounds of poor
pain relief or intolerable adverse events—they derived
increased utility at a more favorable cost. In the base-
case analysis, this was most apparent for second-line
adjunctive cannabis.
No published CEA has addressed the use of smoked
cannabis, the treatment of neuropathic pain, or canna-
bis and cannabinoids in the United States health mar-
ketplace; our study, then, is a novel contribution to the
literature in all three regards. Previous studies have
evaluated the cost-effectiveness of cannabis-based
medicine for the treatment of MS in the European
health marketplace, with conﬂicting results. One com-
bined randomized clinical trial and CEA of dronabinol
to slow disease progression found that the intervention
had no signiﬁcant disease-modifying effect and was
therefore not cost-effective.42 Four published CEAs
evaluated nabiximols versus usual care for the treat-
ment of MS-related spasticity using a willingness-to-
pay threshold of e30,000 per QALY or £30,000 per
QALY. A publicly funded study in the United Kingdom
found that nabiximols were not cost-effective at that
threshold, while industry-funded studies built using
Spain, Germany, Italy, and Wales as health marketplace
settings found nabiximols to be cost-effective.43–46
Our model was sensitive to changes affecting the
quantity of cannabis purchased and, therefore, the
price paid for cannabis. We overestimated quantities
of cannabis consumed daily: dosing of THC was
based on the weight of cannabis cigarette consumed
by participants in the clinical trial by Ellis et al.,6 but
it was impossible to subtract the weight of the paper
used to roll the cigarette. Likewise, the per-gram price
ﬁgure used in their analysis may have overestimated
cost, as the majority of transactions used to calculate
it were subject to a 37% excise tax not levied on medic-
inal cannabis.37,47 In practice, patients in the United
Table 3. Outcomes of Alternate Time Horizon,
Adverse Event Rate, and Cannabis Wastage Analyses
Usual care
First-line
adjunctive
cannabis
Second-line
adjunctive
cannabis
Third-line
adjunctive
cannabis
Five-year time horizon
Average QALYs 2.024 2.057 2.098 2.088
Average cost $27,505 $29,035 $29,327 $28,865
ICER REF Dominated $45,968 $21,143
Ten-year time horizon
Average QALYs 3.469 3.507 3.563 3.557
Average cost $47,937 $49,926 $50,333 $49,853
ICER REF Dominated $81,591 $21,834
Alternate cannabis AE rates
Average QALYs 0.476 0.482 0.486 0.479
Average cost $6,379 $7,643 $7,167 $6,688
ICER REF Dominated $73,193 Ext. dominated
Cannabis wastage
Average QALYs 0.476 0.488 0.489 0.480
Average cost $6,383 $7,875 $7,430 $6,797
ICER REF Dominated $83,865 Ext. dominated
All costs are in 2017 U.S. dollars. ICERs are calculated referent to the
next least costly nondominated treatment option.
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States pay a variety of prices, which may be much
higher in some settings or signiﬁcantly lower, especially
if patients grow their own cannabis.
Our model incorporates parameters from a single
clinical trial of good quality, a year-long observational
study, and published market data to simulate the use
of cannabis in clinical practice as comprehensively as
possible. Nonetheless, our model has several limitations.
Existing clinical trials of cannabis have been of short du-
ration, we overestimated the dose of cannabis consumed
because the weight of the paper used to roll the cigarettes
was included in measurements of the dose, and the ob-
servational cohort study may under- or overestimate ad-
verse event rates related to long-term use of cannabis.
Due to the limited scope of published clinical trials of
cannabis and the absence of CEA in HIV neuropathy,
we derived cannabis efﬁcacy parameters from partici-
pants with HIV neuropathy and then applied them to
a published CEAmodel of pDPN. However, there is ev-
idence in the literature to suggest that this is a reason-
able extrapolation: pain relief from standard therapy
agents is similar in HIV neuropathy and pDPN48–53;
treatment guidelines for both pDPN and HIV neurop-
athy recommend standard therapy agents as ﬁrst- or
second-line agents54–56; short-term effects of smoked
cannabis for pDPN are consistent with effects observed
in trials on HIV neuropathy.6–8,11
Another limitation is that there are no studies of in-
haled medical cannabis examining ‘‘tolerance’’ to can-
nabis over the long-term, and tolerance was not
accounted for in the model. However, a study of canna-
binoids in MS suggest continued analgesic effects over
time.57 Furthermore, our model inputs for adverse
events were derived from an observational cohort, in
which patients administered their study cannabis by
multiple routes, including smoking, vaporization, and
oral consumption (the majority of patients—61%—
using some combination of the three35). As such,
they may not be generalizable to an exclusively smoked
cannabis regimen.
Because there are no available clinical trial data on
long-term consequences of regular licit, smoked medic-
inal cannabis use—with data on long-term outcomes
derived from studies of recreational or other illicit
use58—we did not structure provisions for latent, insid-
ious or long-term adverse effects into the model.
Conclusion
Notwithstanding limitations, this is the ﬁrst published
CEA of inhaled cannabis for any condition. The results
of our analysis indicate that should long-term conse-
quences and efﬁcacy be similar to what has been ob-
served in published trials, smoked medicinal cannabis
is a useful tool from a cost-effectiveness perspective
for the treatment of chronic neuropathic pain. Judicious
use of medicinal cannabis alongside standard therapy
agents may be particularly beneﬁcial to patients with re-
fractory pain and to active cannabis users. Our ﬁndings
are concordant with clinical experience and published
guidelines that recommend consideration of cannabis
for patients nonresponsive to initial treatment.16
The data demonstrate the importance of cost to the
ultimate utility of medicinal cannabis in practice. In ad-
dition to exploring the efﬁcacy and safety proﬁle of
cannabis-based medicine, including cannabis or canna-
binoids as monotherapy for neuropathic pain, future
research should evaluate its economic feasibility and
inﬂuence public policy to assure that this potentially
useful intervention is accessible. Characterizing the
cost-effectiveness of medicinal cannabis will inform fu-
ture research and policy as to whether this treatment
modality is promising from a health economics and
population health perspective, over and above its
emerging efﬁcacy in clinical trials.
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